The present disclosure relates to implantable devices such as vascular grafts, and more particularly, relates to low bleed tubular vascular grafts with a tapered length portions such that opposing ends of the graft have different inside diameters.
The use of implantable medical devices in the treatment of diseased vasculature and other body conduits has become commonplace in the medical field. These implantable devices can be used in applications where a low bleed implantable device is desired wherein the implantable device may be punctured (e.g., by suture needles and/or dialysis needles) and upon subsequent removal of the puncturing needle there is minimal fluid loss at the needle puncture site. Some of these implantable medical devices (e.g., a graft) may also be used in applications (e.g., dialysis) where a graft may benefit from a taper portion along its length, whereby one end of the graft has a larger inside diameter than an opposing end. A typical graft that has been designed for needle puncture may include an elastomeric material (e.g., silicone) that has a consistent wall thickness along the length of the graft. A typical graft, for example, a porous expanded polytetrafluoroethylene (ePTFE) graft that has been manufactured with a taper has a wall thickness at large end of the taper that is less than a wall thickness at a small end of the taper, therefore potentially limiting flexibility.
These tapered grafts and low bleed grafts have functioned well in many applications, particularly for dialysis applications. These previously known grafts still have limitations and leave room for improvements, especially in difficult applications such as where a low bleed graft and a taper is desired. Therefore, it remains desirable to provide a low bleed taper graft that has desirable handling attributes. There remains a need among vascular surgeons for such a graft.
This document describes an implantable medical device, such as a vascular graft, incorporating a taper length portion and having low bleed characteristics following puncture by and removal of a needle such as a dialysis needle or a suture needle. A vascular graft per this disclosure may comprise a tubular structure having a first (Inner) layer, an intermediate layer, an optional second (outer) layer, and a length wherein said intermediate layer comprises an elastomer; wherein said tubular structure has a proximal end with proximal inside and outside diameters, and a distal end with a distal inside and outside diameters, wherein the distal inner and outer diameters are greater than the proximal inside and outside diameters respectively, and there is a transition length portion located between the proximal diameters and the distal diameters; and wherein the intermediate layer has a variable thickness along the length of the tubular structure and particularly along the transition length portion, wherein the thickness of the intermediate layer is greater at the distal end than it is at the proximal end. The first inner layer and the second outer layer may, in contrast to the intermediate layer (and counterintuitively), also be of variable thickness along the transition length portion but vary from being thicker at the proximal end to thinner at the distal end.
It is apparent that additional layers of materials as desired may be added to the three layer constructs described herein, resulting in constructs having four, five, six or more layers. In one embodiment, a first, inner layer may be a porous (e.g., ePTFE) material, an intermediate layer may be a non- porous (e.g., an elastomer) material, and an optional second, outer layer may be a porous (e.g., ePTFE) material. All materials should be suitable implantable materials. Suitable porous materials in addition to ePTFE may, for example, include implantable fabrics (e.g., polyethylene terephthalate) and porous polyurethanes and polyethylenes. Intermediate layer materials may include elastomers such as silicones and polyurethanes. These intermediate layer materials would most typically be non-porous materials, but porous versions of these same materials may also be used for this layer.
As layers extend along proximal, transition, and distal length portions; the materials making up the various layers may extend continuously and integrally between opposing ends of the graft. Alternatively, the various layers may be discreet, resulting in material boundaries between various length portions.
The accompanying drawings are included to provide a further understanding of the present disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure, and together with the description serve to explain the principles of the present disclosure.
An implantable device (e.g., a vascular graft) in accordance with the present disclosure may be used in various applications. The implantable device 100 may be used in an arterial venous application (e.g., dialysis) as shown by example in
An implantable device 100 can have various configurations. For example, as shown in the longitudinal cross section of
The transition portion 308 has a transition portion length 324 between a transition portion proximal end 304 and transition portion distal end 300. The transition portion 308 may comprise a first (inner) layer 310 having a transition portion first layer wall thickness 312. The transition portion first layer wall thickness 312 may vary along the transition portion length 324. The transition portion first layer wall thickness 312 may be thicker on the transition portion proximal end 304 than the transition portion first layer wall thickness 312 at the transition portion distal end 300. Alternatively, the transition portion first layer wall thickness 312 may be thinner on the transition portion proximal end 304 than the transition portion first layer wall thickness 312 at the transition portion distal end 300.
The first layer 310 has a first layer first surface 358 and a first layer second surface 360, as shown in
The transition portion 308 may also have an intermediate layer 314 adjacent to at least a portion of the first layer 310. For example, as shown in
The intermediate layer 314 has a transition portion intermediate layer wall thickness 316 that varies along the transition portion 308. The transition portion intermediate layer wall thickness 316 may taper between the transition portion proximal end 304 and the transition portion distal end 300 as shown in
The intermediate layer 314 may also be juxtaposed to an optional additional layer (e.g., second layer 318). Alternatively, the intermediate layer 314 may be partially imbibed into another layer, for example, the second porous layer 318, in the surface region of the second layer 318 that is adjacent to the intermediate layer 314. The intermediate layer 314 may extend proximally and/or distally beyond the transition portion 308.
The transition portion 308 may have a second (outer) layer 318. For example, as shown in
In certain instances, the intermediate layer 314 may taper between the transition portion proximal end 304 and the transition portion distal end 300. In certain instances, the intermediate layer 314 may taper such that the intermediate layer wall thickness 316 is zero or approximately zero at any point within the transition portion length 324 (as is represented by the dotted lines showing the boundary of the intermediate layer 314). In certain instances, the intermediate layer 314 may taper such that the intermediate layer wall thickness 316 is zero or approximately zero the at the transition portion proximal end 304. As shown in
Also as shown in
Also as shown in
In certain instances, the proximal portion intermediate layer 314 may taper between the transition portion proximal end 304 and the proximal end 106. In certain instances, the intermediate layer 314 may taper such that the intermediate layer wall thickness 332 is zero or approximately zero at any point within the proximal portion length 325 (as is represented by the dotted lines showing the boundary of the intermediate layer 314). In certain instances, the intermediate layer 314 may taper such that the intermediate layer wall thickness 332 is zero or approximately zero the at the proximal end 106. The decrease in thickness of the intermediate layer 314 in the proximal portion 322 may enhance the ease of puncture of the proximal portion 322 by a suture (or the like) to secure the implantable device 100 to a patient. As shown in
The transition portion 308 has a transition portion proximal end 304 (
The proximal portion 322 may have various wall thickness configurations. In one example, as shown in
The distal portion 338 may have various wall thickness configurations. In one example, as shown in
The implantable device 100 may have various overall wall thickness configurations. For example, as shown in
An overall wall thickness measured along the implantable device 100 may comprise at least one polymer layer (e.g., ePTFE) and at least one elastomer layer (e.g., silicone). The implantable device 100 may have a transition portion 308 comprising a transition portion overall wall thickness 354 (as shown in
The implantable device 100 may also have a transition portion 308 comprising a transition portion overall wall thickness 356 (
In addition to the ratios described above, the overall wall thickness 356 at the transition portion proximal end 304 may be greater than the overall wall thickness 354 at the transition portion distal end 300.
The implantable device 100 may have various portions. For example, it may have a proximal portion 322 with a proximal portion length 325, a transition portion 308 with a transition portion length 324, and a distal portion 338 with a distal portion length 326, as shown in
An implantable device 100 may be manufactured in various ways. One example is described herein, as follows. A 145 cm long mandrel having a 7 mm diameter portion by 120 cm long, a 3.84 mm diameter portion by 20 cm long, and a 5 cm long tapered portion between the 7 mm diameter portion and the 3.84 mm diameter portion was obtained (i.e., a 7-4 mm tapered mandrel). A 3.60 mm diameter extruded ePTFE tube with a wall thickness of 0.08 mm was obtained (ePTFE first tube). The ePTFE first tube has a lumen extending along the ePTFE first tube. The 7-4 mm tapered mandrel was then inserted into the ePTFE first tube. The ePTFE first tube was extended so that any wrinkling of the ePTFE first tube was minimized. The ePTFE first tube was then helically wrapped with a 1.27 cm wide ePTFE film tape entirely along the length of the ePTFE first tube. The mandrel with the ePTFE first tube was then heated in a convection oven at 370 degrees C. for 12 minutes. Following removal from the oven, the ePTFE first tube on the 7-4 mm tapered mandrel was then allowed to air cool in ambient air until the ePTFE tube reached approximately room temperature. This example produced an ePTFE first tube with approximately a 7 mm inside diameter length portion, a 4 mm inside diameter length portion, and a tapered length portion extending between the 7 mm inside diameter length portion and the 4 mm inside diameter length portion. The 7 mm inside diameter length portion had a wall thickness of approximately 0.08 mm and the 4 mm inside diameter length portion had a wall thickness of approximately 0.10 mm. The tapered length portion had a varying wall thickness (i.e., varying from 0.08 mm to 0.10 mm) between the 7 mm inside diameter length portion and the 4 mm inside diameter length portion.
A second ePTFE tube with a taper was manufactured as follows. A 145 cm long mandrel with a 6.50 mm diameter portion by 110 cm long, a 3.80 mm diameter portion by 30 cm long, and a 5 cm long tapered length portion between the 6.50 mm diameter length portion and the 3.80 mm diameter length portion was obtained (6.5 −3.80 mm tapered mandrel). A 6 mm diameter extruded and expanded ePTFE tube with a wall thickness of 0.66 mm was obtained (ePTFE second tube). The 6.50−3.80 mm tapered mandrel was inserted into the ePTFE second tube lumen. The ePTFE second tube was extended so that any wrinkling of the ePTFE second tube was minimized. The ends of the ePTFE second tube were then secured to the mandrel by wrapping an ePTFE film around the ends of the ePTFE second tube. The ePTFE second tube was then helically wrapped with a 1.90 cm wide ePTFE film tape entirely along the length of the ePTFE second tube. The mandrel with the ePTFE second tube was then heated by a convection oven at 370 degrees C. for 12 minutes. Following removal from the oven, the ePTFE second tube on the mandrel was then allowed to air cool in ambient air until the ePTFE second tube and mandrel reached approximately room temperature. The ePTFE second tube was then removed from the mandrel. This procedure resulted in an ePTFE second tube with a 6.5 mm inside diameter length portion, a 3.80 mm inside diameter length portion, and a tapered length portion extending between the 6.50 mm inside diameter length portion and the 3.80 mm inside diameter length portion. The 6.50 mm inside diameter length portion had a wall thickness of approximately 0.76 mm and the 3.80 mm inside diameter length portion had a wall thickness of approximately 0.79 mm. The tapered length portion had a varying wall thickness that tapered between the wall thickness of the 6.50 mm inside diameter length portion and the wall thickness of the 3.80 mm inside diameter length portion. In certain instances, the tapered length portion had a varying wall thickness that tapered between the wall thickness of the 6 mm inside diameter length portion and the wall thickness of the 4 mm inside diameter length portion, and in other instances, the tapered length portion had a varying wall thickness that tapered between the wall thickness of the 5 mm inside diameter length portion and the wall thickness of the 4 mm inside diameter length portion.
The mandrel with the ePTFE first tube was then coated with a layer of silicone (NuSil Technology LLC, Carpinteria, Calif.). An iris apparatus (Standa Ltd., Vilnius, Lithuania) capable of dilating and contracting between 1 mm and 15 mm was obtained. The mandrel with the first ePTFE tube was displaced through the iris contained within an apparatus. The apparatus supplied silicone to the outer surface of the ePTFE first tube and the iris maintained a wall thickness of silicone of approximately 0.53 mm on the ePTFE first tube outer surface (along the larger diameter portion of the ePTFE first tube), 0.30 mm on the smaller diameter portion of the ePTFE first tube, and a varying silicone wall thickness between 0.53 mm and 0.30 mm along the tapered portion of the ePTFE first tube. The silicone was then allowed to partially set by curing in a convection oven for 6.5 minutes at 200 degrees C.
The ePTFE second tube was then enlarged diametrically by pulling the ePTFE second tube over a mandrel. The mandrel had a 9.60 mm outside diameter length portion of approximately 55 cm length and a 5.40 mm outside diameter length portion of 12 cm length with a transition length portion extending between the 5.40 mm outside diameter length portion and the 9.60 mm outside diameter length portion. The ePTFE second tube and mandrel assembly was then heated in a convection oven for approximately 45 seconds at 200 degrees C. The ePTFE second tube distal end inside diameter was enlarged to approximately 9.60 mm over the ePTFE second tube distal end and the ePTFE second tube proximal end inside diameter was enlarged to approximately 5.40 mm on the ePTFE second tube proximal end with the transition length portion extending between the 9.60 mm inside diameter and the 5.40 mm inside diameter.
After the ePTFE second tube was removed from the mandrel, a flare of 12 mm was then created on the ePTFE second tube distal end (i.e., 9.60 mm inside diameter end) with a flaring tool (a mandrel). The ePTFE second tube was then held within the apparatus with the iris to allow the ePTFE first tube with its outer layer of silicone to be inserted into the lumen of the ePTFE second tube. The ePTFE first tube proximal portion was inserted first through the ePTFE second tube distal portion until the transition length portions of the ePTFE first tube and ePTFE second tube were approximately aligned. While the ePTFE first tube was being inserted through the ePTFE second tube the apparatus applied a second layer of silicone approximately 0.15 mm thick (the second layer being thinner than the first layer) onto the ePTFE first tube with silicone outer layer. The second layer of silicone wall thickness was controlled by the iris apparatus. After the second layer of silicone was applied and the ePTFE first tube and ePTFE second tube tapered portions were aligned, the silicone was then allowed to fully set by curing in a convection oven for 15 minutes at 200 degrees C. In this example, an implantable device according to this disclosure was made.
The resulting implantable device had a first layer comprising an ePTFE first (Inner) tube, an intermediate layer comprising silicone, and a second layer comprising an ePTFE second (outer) tube. The implantable device had a transition length portion with a length of 5 cm, a distal length portion with a length of 48 cm and a proximal length portion with a length of 2 cm. Longitudinal cross sections were taken and wall thickness measurements were made (overall wall thickness and intermediate layer wall thickness) with an optical profiler (Unitron Inc., Bohemia N.Y.) along the proximal length portion and the distal length portion of the implantable device. The overall wall thickness in the proximal length portion was approximately 1.25 mm. The intermediate layer wall thickness in the proximal length portion was approximately 0.48 mm. The overall wall thickness in the distal length portion was approximately 1.22 mm and the intermediate layer wall thickness in the distal length portion was 0.70 mm. The overall wall thickness in the transition length portion varied from 1.25 mm near the proximal length portion to 1.22 mm near the distal length portion and the intermediate layer wall thickness in the transition length portion varied from 0.48 mm near the proximal length portion to 0.70 mm near the distal length portion. A ratio of intermediate layer wall thickness to a combination of the ePTFE first tube wall thickness and ePTFE second tube wall thickness in the proximal length portion was approximately 0.63. A ratio of intermediate layer wall thickness to a combination of the ePTFE first tube wall thickness and ePTFE second tube wall thickness in the distal length portion was approximately 1.35 mm.
Implantable devices according to this disclosure may be used in various applications. For example, the implantable device may be used in an arterial venous application such as in dialysis. One end of the implantable device may be attached to a vein, an opposing end may be attached to an artery.
In addition to the teachings described above and claimed below, devices and/or methods having different combinations of the features described above and claimed below are contemplated. As such, the description is also directed to other devices and/or methods having any other possible combination of the dependent features claimed below.
Numerous characteristics and advantages have been set forth in the preceding description, including various alternatives together with details of the structure and function of the devices and/or methods. The disclosure is intended as illustrative only and as such is not intended to be exhaustive. It will be evident to those skilled in the art that various modifications may be made, especially in matters of structure, materials, elements, components, shape, size and arrangement of parts including combinations within the principles of the invention, to the full extent indicated by the broad, general meaning of the terms in which the appended claims are expressed. To the extent that these various modifications do not depart from the spirit and scope of the appended claims, they are intended to be encompassed therein.
This application is a continuation of U.S. patent application Ser. No. 15/173,361, filed Jun. 3, 2016, which claims the benefit of U.S. Provisional Application 62/171,694, filed Jun. 5, 2015, both of which are incorporated herein by reference in their entireties for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
512151 | Briggs | Jan 1894 | A |
3425418 | Chvapil et al. | Feb 1969 | A |
3814137 | Martinez | Jun 1974 | A |
3914802 | Reick | Oct 1975 | A |
3953566 | Gore | Apr 1976 | A |
4133927 | Tomodoa et al. | Jan 1979 | A |
4177334 | Okita | Dec 1979 | A |
4187390 | Gore | Feb 1980 | A |
4193138 | Okita | Mar 1980 | A |
4208745 | Okita | Jun 1980 | A |
4229838 | Sumitomo | Oct 1980 | A |
4279245 | Takagi et al. | Jul 1981 | A |
4283448 | Bowman | Aug 1981 | A |
4304010 | Mano | Dec 1981 | A |
4321711 | Mano | Mar 1982 | A |
4347204 | Takagi et al. | Aug 1982 | A |
4416028 | Eriksson et al. | Nov 1983 | A |
4443511 | Worden et al. | Apr 1984 | A |
RE31618 | Mano | Jul 1984 | E |
4474630 | Planck et al. | Oct 1984 | A |
4478898 | Kato | Oct 1984 | A |
4550447 | Seiler, Jr. et al. | Nov 1985 | A |
4604762 | Robinson | Aug 1986 | A |
4613544 | Burleigh | Sep 1986 | A |
4619641 | Schanzer | Oct 1986 | A |
4657544 | Pinchuk | Apr 1987 | A |
4687482 | Hanson | Aug 1987 | A |
4692369 | Nomi | Sep 1987 | A |
4731073 | Robinson | Mar 1988 | A |
4739013 | Pinchuk | Apr 1988 | A |
4743252 | Martin, Jr. et al. | May 1988 | A |
4743480 | Campbell et al. | May 1988 | A |
4759757 | Pinchuk | Jul 1988 | A |
4787921 | Shibata et al. | Nov 1988 | A |
4804381 | Turina et al. | Feb 1989 | A |
4810749 | Pinchuk | Mar 1989 | A |
4816339 | Tu et al. | Mar 1989 | A |
4850999 | Planck | Jul 1989 | A |
4857069 | Kira | Aug 1989 | A |
4871361 | Kira | Oct 1989 | A |
4875468 | Krauter et al. | Oct 1989 | A |
4877661 | House et al. | Oct 1989 | A |
4882113 | Tu et al. | Nov 1989 | A |
4891407 | Mitchell | Jan 1990 | A |
4921495 | Kira | May 1990 | A |
4932964 | Bittmann et al. | Jun 1990 | A |
4945125 | Dillon et al. | Jul 1990 | A |
4955899 | Dealla Coma et al. | Sep 1990 | A |
4957669 | Primm | Sep 1990 | A |
4969896 | Shors | Nov 1990 | A |
4973609 | Browne | Nov 1990 | A |
5024671 | Tu et al. | Jun 1991 | A |
5026513 | House | Jun 1991 | A |
5061276 | Tu et al. | Oct 1991 | A |
5064593 | Tamaru et al. | Nov 1991 | A |
5066683 | Dillon et al. | Nov 1991 | A |
5071609 | Tu et al. | Dec 1991 | A |
5084065 | Weldon et al. | Jan 1992 | A |
5099557 | Engelsberg | Mar 1992 | A |
5100422 | Berguer et al. | Mar 1992 | A |
5104400 | Berguer et al. | Apr 1992 | A |
5116360 | Pinchuk et al. | May 1992 | A |
5123151 | Uehara et al. | Jun 1992 | A |
5123917 | Lee | Jun 1992 | A |
5128092 | Asaumi et al. | Jul 1992 | A |
5133742 | Pinchuk | Jul 1992 | A |
5152782 | Kowligi et al. | Oct 1992 | A |
5192310 | Herweck et al. | Mar 1993 | A |
5217797 | Knox et al. | Jun 1993 | A |
5229431 | Pinchuk | Jul 1993 | A |
5290271 | Jernberg | Mar 1994 | A |
5320888 | Stevens | Jun 1994 | A |
5354329 | Whalen | Oct 1994 | A |
5358516 | Myers et al. | Oct 1994 | A |
5370681 | Herweck et al. | Dec 1994 | A |
5453235 | Calcote et al. | Sep 1995 | A |
5466252 | Soukup et al. | Nov 1995 | A |
5476589 | Bacino | Dec 1995 | A |
5584876 | Bruchman et al. | May 1996 | A |
5527353 | Schmitt | Jun 1996 | A |
5529820 | Nomi et al. | Jun 1996 | A |
5549664 | Hirata et al. | Aug 1996 | A |
5556426 | Popadiuk et al. | Sep 1996 | A |
5607478 | Lentz et al. | Mar 1997 | A |
5609624 | Kalis | Mar 1997 | A |
5620763 | House et al. | Apr 1997 | A |
5628782 | Myers et al. | May 1997 | A |
5628788 | Pinchuk | May 1997 | A |
5641373 | Shannon et al. | Jun 1997 | A |
5647400 | Jani et al. | Jul 1997 | A |
5665114 | Weadock et al. | Sep 1997 | A |
5700287 | Myers et al. | Dec 1997 | A |
5708044 | Branca | Jan 1998 | A |
5716395 | Myers et al. | Feb 1998 | A |
5716660 | Weadock et al. | Feb 1998 | A |
5718973 | Lewis et al. | Feb 1998 | A |
5735892 | Myers et al. | Apr 1998 | A |
5749880 | Banas et al. | May 1998 | A |
5788626 | Thompson | Aug 1998 | A |
5789047 | Sasaki et al. | Aug 1998 | A |
5800510 | Schmitt | Sep 1998 | A |
5800512 | Lentz et al. | Sep 1998 | A |
5800514 | Nunez | Sep 1998 | A |
5824050 | Karwoski et al. | Oct 1998 | A |
5840240 | Stenoien | Nov 1998 | A |
5843173 | Shannon et al. | Dec 1998 | A |
5851229 | Lentz et al. | Dec 1998 | A |
5851230 | Lentz et al. | Dec 1998 | A |
5866217 | Stenoien et al. | Feb 1999 | A |
5897587 | Martakos et al. | Apr 1999 | A |
5904967 | Ezaki et al. | May 1999 | A |
5910168 | Myers et al. | Jun 1999 | A |
5918643 | Roloff | Jul 1999 | A |
5931865 | Silverman et al. | Aug 1999 | A |
5976192 | McIntyre et al. | Nov 1999 | A |
6001125 | Golds et al. | Dec 1999 | A |
6016848 | Egres et al. | Jan 2000 | A |
6027779 | Campbell et al. | Feb 2000 | A |
6036724 | Lentz et al. | Mar 2000 | A |
6039755 | Edwin | Mar 2000 | A |
6042666 | Karwoski et al. | Mar 2000 | A |
6053939 | Okuda et al. | Apr 2000 | A |
6056970 | Greenawalt et al. | May 2000 | A |
6080198 | Lentz et al. | Jun 2000 | A |
6099557 | Schmitt | Aug 2000 | A |
6159565 | Campbell et al. | Dec 2000 | A |
6165211 | Thompson | Dec 2000 | A |
6187054 | Colone et al. | Feb 2001 | B1 |
6203735 | Edwin | Mar 2001 | B1 |
6267834 | Shannon et al. | Jul 2001 | B1 |
6287337 | Martakos et al. | Sep 2001 | B1 |
6319279 | Shannon et al. | Nov 2001 | B1 |
6328762 | Anderson et al. | Dec 2001 | B1 |
6338904 | Patnaik et al. | Jan 2002 | B1 |
6346273 | Saettone | Feb 2002 | B1 |
6368347 | Maini et al. | Apr 2002 | B1 |
6416537 | Martakos et al. | Jul 2002 | B1 |
6428571 | Lentz et al. | Aug 2002 | B1 |
6436135 | Goldfarb | Aug 2002 | B1 |
6517571 | Brauker et al. | Feb 2003 | B1 |
6517858 | LeMoel et al. | Feb 2003 | B1 |
6521284 | Parsons et al. | Feb 2003 | B1 |
6534084 | Vyakarnam et al. | Mar 2003 | B1 |
6541589 | Baillie | Apr 2003 | B1 |
6547820 | Staudenmeier | Apr 2003 | B1 |
6589468 | Schmitt | Jul 2003 | B1 |
6663614 | Carter | Dec 2003 | B1 |
6712919 | Ruefter et al. | Mar 2004 | B2 |
6716239 | Sowinski | Apr 2004 | B2 |
6719783 | Lentz et al. | Apr 2004 | B2 |
6790226 | Edwin et al. | Sep 2004 | B2 |
6814753 | Schmitt | Nov 2004 | B2 |
6827737 | Hill et al. | Dec 2004 | B2 |
6863686 | Shannon et al. | Mar 2005 | B2 |
6926735 | Henderson | Aug 2005 | B2 |
6939377 | Jayaraman et al. | Sep 2005 | B2 |
7056336 | Armstrong et al. | Jun 2006 | B2 |
7056387 | Van Der Steur | Jun 2006 | B2 |
7108701 | Evens et al. | Sep 2006 | B2 |
7147617 | Henderson et al. | Dec 2006 | B2 |
7244271 | Lentz et al. | Jul 2007 | B2 |
7297158 | Jensen | Nov 2007 | B2 |
7306729 | Bacino et al. | Dec 2007 | B2 |
7351257 | Kaldany | Apr 2008 | B2 |
7396363 | Frid | Jul 2008 | B2 |
7452374 | Hain et al. | Nov 2008 | B2 |
7510571 | Spiridigliozzi et al. | Mar 2009 | B2 |
7531611 | Sabol et al. | May 2009 | B2 |
7553326 | Sweet et al. | Jun 2009 | B2 |
7560006 | Rakos et al. | Jul 2009 | B2 |
8029563 | House | Oct 2011 | B2 |
8637144 | Ford | Jan 2014 | B2 |
8906087 | House | Dec 2014 | B2 |
9139669 | Xu et al. | Sep 2015 | B2 |
9814560 | Cully et al. | Nov 2017 | B2 |
10357385 | Schlaud | Jul 2019 | B2 |
20020058991 | Schmitt | May 2002 | A1 |
20020138129 | Armstrong | Sep 2002 | A1 |
20030004559 | Lentz et al. | Jan 2003 | A1 |
20030027775 | Wallace | Feb 2003 | A1 |
20030060871 | Hill et al. | Mar 2003 | A1 |
20030100859 | Henderson et al. | May 2003 | A1 |
20030139806 | Haverkost et al. | Jul 2003 | A1 |
20030153983 | Miller et al. | Aug 2003 | A1 |
20040000858 | Hwang et al. | Jan 2004 | A1 |
20040024442 | Sowinski et al. | Feb 2004 | A1 |
20040033364 | Spiridigliozzi et al. | Feb 2004 | A1 |
20040049264 | Sowinksi et al. | Mar 2004 | A1 |
20040054406 | Dubson et al. | Mar 2004 | A1 |
20040122507 | Henderson | Jun 2004 | A1 |
20040182511 | Rakos et al. | Sep 2004 | A1 |
20040193242 | Lentz et al. | Sep 2004 | A1 |
20040215337 | Hain | Oct 2004 | A1 |
20040265352 | Kaldany | Dec 2004 | A1 |
20050137677 | Rush | Jun 2005 | A1 |
20050187607 | Akhtar et al. | Aug 2005 | A1 |
20050203606 | VanCamp | Sep 2005 | A1 |
20050240261 | Rakos | Oct 2005 | A1 |
20050249776 | Chen et al. | Nov 2005 | A1 |
20060041318 | Shannon | Feb 2006 | A1 |
20070116736 | Argentieri et al. | May 2007 | A1 |
20070276474 | Llanos et al. | Nov 2007 | A1 |
20070293808 | Williams et al. | Dec 2007 | A1 |
20080027534 | Edwin et al. | Jan 2008 | A1 |
20080097592 | Fitzpatrick | Apr 2008 | A1 |
20080195026 | Kim | Aug 2008 | A1 |
20080195079 | Moore et al. | Aug 2008 | A1 |
20090270973 | Chen et al. | Oct 2009 | A1 |
20110054586 | Mayberry | Mar 2011 | A1 |
20120130477 | Gessaroli | May 2012 | A1 |
20150157444 | Cully et al. | Jun 2015 | A1 |
20180092733 | Cully et al. | Apr 2018 | A1 |
Number | Date | Country |
---|---|---|
1466165 | Jan 2004 | CN |
1486165 | Mar 2004 | CN |
1976648 | Jun 2007 | CN |
103857416 | Jun 2014 | CN |
0117072 | Aug 1984 | EP |
0256748 | Feb 1988 | EP |
0266035 | May 1988 | EP |
0391586 | Oct 1990 | EP |
656196 | Jul 1995 | EP |
1131113 | Feb 2000 | EP |
1101458 | May 2001 | EP |
1925270 | May 2008 | EP |
2033232 | May 1980 | GB |
1590101 | May 1981 | GB |
2222954 | Mar 1990 | GB |
6343688 | Dec 1994 | JP |
2739420 | Mar 1995 | JP |
8238263 | Sep 1996 | JP |
11099163 | Apr 1999 | JP |
5176947 | Jul 2010 | JP |
5474514 | Jun 2011 | JP |
5925725 | Nov 2014 | JP |
WO-1995010247 | Apr 1995 | WO |
WO-1996007370 | Mar 1996 | WO |
WO-9826731 | Jun 1998 | WO |
WO-2001021107 | Mar 2001 | WO |
WO-2001032382 | May 2001 | WO |
WO-2001067991 | Sep 2001 | WO |
WO-2002013675 | Feb 2002 | WO |
WO-03015837 | Feb 2003 | WO |
WO-2003084440 | Oct 2003 | WO |
WO-2004060209 | Jul 2004 | WO |
WO-2004096307 | Nov 2004 | WO |
WO-2006007214 | Jan 2006 | WO |
WO-2006026725 | Mar 2006 | WO |
WO-2006038031 | Apr 2006 | WO |
WO-2006058322 | Jun 2006 | WO |
WO-2006085044 | Aug 2006 | WO |
WO-2007061787 | May 2007 | WO |
WO-2007113494 | Oct 2007 | WO |
WO-2007127802 | Nov 2007 | WO |
WO-2007137211 | Nov 2007 | WO |
Entry |
---|
Berman M, Pearce W, et al, The use of Gore-Tex E-PTFE bonded to silicone rubber as an alloplastic implant material. Laryngoscope 1986; v96 n5: 480-483. |
European Search Report from EP18208417.8, dated Apr. 24, 2019, 8 pages. |
GORE® Acuseal Cardiovascular Patch Product Information, Jun. 2014, 40 pages. |
International Search Report and Written Opinion for PCT/US2014/068411 dated Feb. 12, 2015, corresponding to U.S. Appl. No. 14/557,927, 9 pages. |
International Search Report and Written Opinion for PCT/US2016/035857 dated Aug. 4, 2016, corresponding to U.S. Appl. No. 15/173,361, 11 pages. |
LeMatire Expedial Vascular Access Graft Product Information/Instructions For Use. |
Lumsden AB, Chen C et al. Nonporous silicone polymer coating of expanded polytetrafluoroethylene grafts reduces graft neointimal hyperplasia in dog and baboon models. Journal of Vascular Surgery 1996; v24 n5: 825-833. |
Perma-Seal Dialysis Access Graft Instructions for use. |
Perma-Seal Dialysis Access Graft Patient Education Brochure. |
Sonoda H, Takamizawa K et al. Coaxial double-tubular compliant arterial graft prosthesis: time-dependent morphogenesis and compliance changes after implantation. J Biomed Mater Res 2003; 65A: 170-181. |
Sonoda H, Takamizawa K et al. Small-diameter compliant arterial graft prosthesis: Design concept of coaxial double tubular graft and its fabrication. J Biomed Mater Res 2011; 55: 266-276. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/068411, dated Jun. 16, 2016, 7 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/035857, dated Dec. 14, 2017, 8 pages. |
International Search Report and Written Opinion for PCT/US2014/068411 dated Feb. 12, 2015, corresponding to U.S. Appl. No. 14/557,927, 5 pages. |
LeMatire Expedial Vascular Access Graft Product Information/Instructions for Use, 3 pages. |
Perma-Seal Dialysis Access Graft Instructions for use, 14pages. |
Perma-Seal Dialysis Access Graft Patient Education Brochure, 5 pages. |
Number | Date | Country | |
---|---|---|---|
20190343663 A1 | Nov 2019 | US |
Number | Date | Country | |
---|---|---|---|
62171694 | Jun 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15173361 | Jun 2016 | US |
Child | 16519078 | US |